Segmentation Dice
0.95 Dice coefficient, average
- EndpointSegmentation overlap
- Population82 independent 3D T1 MRI studies from children aged 24-36 months
- Tested versionGyriCalc 1.0.0 configuration submitted in K250686
FDA-cleared profile
NeuroSpectrum Insights Corp. · MRI · FDA-cleared (510(k))
Authorized purpose: Adjunctive quantitative brain-mapping report for qualified clinical interpretation of children 24-36 months, providing regional volume, surface-area and local-gyrification measures from 3D T1 MRI.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Adjunctive quantitative brain-mapping report for qualified clinical interpretation of children 24-36 months, providing regional volume, surface-area and local-gyrification measures from 3D T1 MRI.
Evidence takeaway. Evidence from the reviewed source record: The FDA-described independent test used 82 T1 MRI studies from 82 children aged 24-36 months, with six experts providing reference segmentations. Average Dice was 0.95. Reported volume MAE ranged from 0.45% to 12.1%, surface-area MAE from 0.33% to 12.6%, and gyrification error from 0.04% to 0.89%; the source identifies several regions exceeding 10% volume or surface-area error.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
The cleared endpoints are segmentation and quantitative agreement measures, not disease-detection sensitivity.
The cleared endpoints are segmentation and quantitative agreement measures, not disease-detection specificity.
0.95 Dice coefficient, average
0.45 percent absolute error, lower endpoint of reported range
12.1 percent absolute error, upper endpoint of reported range
0.33 percent absolute error, lower endpoint of reported range
12.6 percent absolute error, upper endpoint of reported range
0.04 percent error, lower endpoint of reported range
0.89 percent error, upper endpoint of reported range
K250686
FDA reports average Dice 0.95, volume MAE 0.45%-12.1%, surface-area MAE 0.33%-12.6% and gyrification error 0.04%-0.89%. Several regional volume/surface values exceeded 10%; no averaging is added here.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.
Price not public here; enter your quote
Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.
This is a commercialization-plan statement, not a current quote or reimbursement amount.
This is a commercialization-plan statement, not a current quote or reimbursement amount.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: 3D T1-weighted DICOM brain MRI acquired at 1.5T or 3T; the ideal isotropic resolution and slice thickness are 1 mm.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-07 · FDA 510(k) K250686: GyriCalc
Source context, not route validation: The FDA submission describes DICOM MRI input and PDF report output; public buyer material describes a processing-center workflow, while local DICOM routing and report delivery require confirmation.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-07 · FDA 510(k) K250686: GyriCalc
Source context, not route validation: The reviewed public filing describes completed MRI studies being sent to a NeuroSpectrum Insights processing center and a PDF report being delivered to the ordering clinician.
Scope: Product family. The filing describes the company's planned commercialization workflow and does not establish current availability or a site-specific service commitment.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-06 · NeuroSpectrum Insights commercialization filing (GyriCalc)
Source context, not route validation: Automatic labels, visualizations and quantitative measures for brain-structure volume, surface area and local gyrification index, delivered as a PDF report.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-07 · FDA 510(k) K250686: GyriCalc
Unresolved route: Automatic labels, visualizations and quantitative measures for brain-structure volume, surface area and local gyrification index, delivered as a PDF report.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-07 · FDA 510(k) K250686: GyriCalc
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The filing describes the company's planned commercialization workflow and does not establish current availability or a site-specific service commitment.
The cleared product produces a PDF report with regional volume, surface-area and local-gyrification measures.
exact submission · checked 2026-09-07The public commercialization filing describes an ordering clinician sending a completed MRI to a NeuroSpectrum Insights processing center and receiving a PDF report.
product family · checked 2026-09-06The filing describes a planned workflow and does not establish current availability, turnaround, contract terms or security controls.
The official GyriCalc page describes correction for motion, intensity inhomogeneity and other artifacts, segmentation of cortical regions, and standardized qualitative/quantitative reporting.
exact product version · checked 2026-09-06Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, sec filing, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Bounded web search on 2026-10-26 (query: "GyriCalc NeuroSpectrum reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.
The reviewed product page and filing do not establish exact-release security controls, retention or assurance documentation.
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
8 sources - 3 history items
Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, reportedSensitivity, reportedSpecificity, evidenceMetrics, evidenceStudies
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: clinicalUse, output, limitations, implementationCapabilities
Scope: economics, implementationCapabilities
Regulatory record
510(k)
Research record
fda record reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Imeka Solutions, Inc.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
BeauBrain Healthcare, Inc.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Siemens Healthcare GmbH
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Imeka Solutions, Inc.
Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history